Bluebird bio's exit from Europe last year signals rough seas ahead for gene therapy developers, who are trying to gain market access for their products. Evidently, bluebird bio couldn’t strike deals with European payers for its EMA-approved gene therapies, Zynteglo (beti-cel) and Skysona (eli-cel).
Subscribe to:
Post Comments (Atom)
< + > Happy New Year!
Happy New Year to all of you! 2025 flew by here at Healthcare IT Today. Hopefully it was an amazing year for you. 2026 is shaping up to ...
No comments:
Post a Comment